/
you're reading...

Cancer / Oncology

Kolltan Pharmaceuticals announces KTN0158 preclinical data at ESMO 2015

Kolltan Pharmaceuticals, Inc. today announced the presentation of data from a preclinical study evaluating KTN0158 in dogs with spontaneous mast cell tumors.

Read full story

Archives